Acasti Pharma (ACST) News Today C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCROctober 29, 2024 | msn.comLife Sciences Virtual Investor Forum Agenda Announced for September 19thSeptember 16, 2024 | finance.yahoo.comACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025August 9, 2024 | markets.businessinsider.comAcasti Pharma Inc. (ACST)April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. Class AMarch 14, 2024 | edition.cnn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 25, 2024 | msn.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsFebruary 12, 2024 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?December 25, 2023 | finance.yahoo.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 14, 2023 | investing.comAcasti Pharma Inc Class A ACSTNovember 11, 2023 | morningstar.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherSeptember 26, 2023 | benzinga.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 6, 2023 | technews.tmcnet.comAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsAugust 11, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finanznachrichten.deAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 22, 2023 | finance.yahoo.comACST - Acasti Pharma Inc.June 20, 2023 | sg.finance.yahoo.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 7, 2023 | theglobeandmail.comAcasti Pharma announces CEO transitionApril 4, 2023 | seekingalpha.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 16, 2023 | morningstar.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 8, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 4, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayMarch 1, 2023 | finance.yahoo.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?February 28, 2023 | msn.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18January 13, 2023 | benzinga.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comAcasti Pharma to Present at Q4 Investor SummitNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialNovember 8, 2022 | tmcnet.comAcasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)September 17, 2022 | theglobeandmail.comAcasti Pharma to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 14, 2022 | finance.yahoo.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia TelangiectasiaSeptember 13, 2022 | it.tmcnet.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic NeuralgiaJuly 27, 2022 | finance.yahoo.comStock Day Media: Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 9, 2022 | finanznachrichten.deAcasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 7, 2022 | finance.yahoo.comAcasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call TranscriptJune 21, 2022 | seekingalpha.comAcasti Pharma reports GAAP EPS of $0.27 for FY2022June 21, 2022 | seekingalpha.comAcasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramMay 23, 2022 | stockhouse.comAcasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thMay 12, 2022 | apnews.comAcasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16thMarch 9, 2022 | finance.yahoo.comAcasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallFebruary 7, 2022 | finance.yahoo.comThinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?December 22, 2021 | benzinga.comAcasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndNovember 24, 2021 | finance.yahoo.comAcasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallNovember 4, 2021 | finance.yahoo.comAcasti Pharma outlines key benefits of recent Grace Therapeutics acquisitionOctober 8, 2021 | proactiveinvestors.comAcasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanOctober 6, 2021 | finance.yahoo.comAcasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104September 29, 2021 | benzinga.comWhy Shares of Acasti Pharma Slumped TuesdayAugust 31, 2021 | msn.comAcasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq ComplianceAugust 28, 2021 | benzinga.com Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL. >> Get Your FREE Wealth Protection Guide << ACST Media Mentions By Week ACST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼0.840.46▲Average Medical News Sentiment ACST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼10▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EQ News Today CI Canadian Convertible Bond ETF Common News Today Moneta Gold News Today BioRem News Today Canadian Gold News Today Relevant Gold News Today Aeterna Zentaris News Today Ascendant Resources News Today Niobay Metals News Today iMetal Resources News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:ACST) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
